EFLUELDA
Sponsors
Gentofte Hospital, Sanofi Pasteur, GlaxoSmithKline Biologicals, GlaxoSmithKline Biologicals, Janssen Vaccines & Prevention B.V., CHU De Liege, Complexo Hospitalario Universitario De Santiago
Conditions
Healthy volunteers (prevention of influenza infection)Hematological cancerPrevention of influenza infection in adults aged 65-79 yearsPrevention of influenza infection in older adultsPrevention of invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease
Phase 1
Phase 3
A Single-Blind randomized trial of High-Dose versus Standard-Dose Inactivated Influenza Vaccine in Adult Patients Treated for an Hematological Cancer (Flu-Hemato-Rando study)
RecruitingCTIS2023-505357-40-00
Start: 2023-09-18Target: 180Updated: 2023-08-23
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older
CompletedCTIS2023-504168-40-00
Start: 2023-11-06End: 2024-07-26Target: 400Updated: 2024-06-11
Phase 4
A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults
CompletedCTIS2022-500657-17-00
Start: 2022-09-10End: 2025-08-31Target: 339700Updated: 2024-09-27
Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in adults aged 65 to 79 years in Galicia, Spain
RecruitingCTIS2023-506977-36-00
Start: 2023-10-26Target: 114011Updated: 2023-09-13